Table 2.
Characteristics of patients initiated on stavudine- and zidovudine-based regimens.
| Characteristics | Stavudine (N = 208) | Zidovudine (N = 215) | P value |
|---|---|---|---|
| Gender, male. N (%) | 72 (34.6) | 96 (44.6) | 0.035 |
| Age, (5 years), median (IQR) | 38 (33–43) | 39 (34–46) | 0.131 |
| ART duration (years), median (IQR) | 2.5 (1.8–2.9) | 2.7 (1.8–3.3) | 0.016 |
| Initial CD4+ counts, median (IQR) | 94 (30.5–171) | 89 (38–166) | 0.888 |
| Initial body weight (Kg), median (IQR) | 53.8 (48.3–61.5) | 54 (48–60) | 0.784 |
| Peak body weight, median (IQR) | 63 (57–71) | 63 (57–68) | 0.387 |
| BMI >25 at study enrolment | 57 (27.4) | 56 (26.1) | 0.752 |
| Systolic blood pressure (mmHg), median (IQR) | 120 (110–130) | 110 (110–120) | <0.001 |
| Hypertension, N (%)* | 33 (15.9) | 16 (7.4) | 0.007 |
| CD4 at study enrolment >200 cells/μL | 175 (85.0) | 153 (72.5) | 0.002 |
| Abnormal waist to hip ratio+ | 0.94 (0.88–0.99) | 0.91 (0.88–0.95) | <0.001 |
| Family history of hypertension, N (%) | 90 (43.7) | 66 (30.7) | 0.006 |
| Family history diabetes mellitus, N (%) | 42 (20.4) | 34 (15.8) | 0.223 |
| Lipodystrophy, N (%) | 74 (35.8) | 14 (6.7) | <0.001 |
| WHO stage III and IV, N (%) | 151 (72.6) | 166 (77.2) | 0.274 |
N: number; IQR: interquartile range; WHO: World Health Organization; ART: antiretroviral treatment; BMI: body mass index.
*Hypertension defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.
+Waist to hip ratio was categorized into abnormal if the value was >0.94 for males and >0.8 for females.